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The nail matrix contains melanocytes in the epidermal 
basal layer, but pigment is not visible in the gross ana-
tomy of the nail plate in Caucasians. Hyperpigmentation 
due to an increase in melanogenesis, and subsequently 
melanin pigment, in the nail may be induced by certain 
drugs, tumours or endocrinological diseases (1–5). The 
whole nail may be affected, whilst some drugs or tumours 
produce longitudinal or vertical bands (3). Importantly, 
longitudinal pigmented bands are a normal finding in 
subjects of darker pigmented races (6).
We wish to report a case of benign melanonychia 
striata due to chemotherapy that was confirmed by 
histological examination.
CASE REPORT
A 39-year-old Caucasian woman reported the develop-
ment of a bright brown band in the middle of her right 
thumb-nail over the last 3 months (Fig. 1a). Because 
of fear of malignancy she was referred by her primary 
physician to our outpatient clinic for nail biopsy. Clini-
cally, the brown band was wider at the proximal nail 
matrix (2.5 mm) and narrower at the distal nail plate 
(2.0 mm). Apart from fear of malignancy and concern 
about the cosmetic appearance, the patient reported no 
other symptoms. No other nails on her hands or feet 
were affected. Four months previously a chemotherapy 
regimen, including docetaxel, cyclophosphamide and 
doxorubicin, was initiated to treat breast cancer. Other-
wise, the patient’s and family’s past medical history 
were unremarkable.
Besides diffuse non-scarring alopecia due to chemo-
therapy, physical examination showed no other skin or 
mucosal pathology. Nail dermatoscopy using DermoGe-
nius (Biocam GmBH, Regensburg, Germany) showed 
streak-like homogeneous brownish discoloration with 
progression into the proximal nail fold (Fig. 1b). Im-
portantly, neither pigment nests nor pigment dots were 
discernible. As only one nail was affected and the patient 
was very concerned, a biopsy directly from the nail 
matrix tissue was performed.
Histological examination showed no melanocytic aty-
pia, despite serial sectioning of the entire tissue block. 
Melanin staining was strongly positive, showing that 
the hyperpigmentation was due to melanin production 
(Fig. 2a). Iron (to exclude subungual bleeding; Fig. 2b) 
and periodic acid-Schiff (PAS) stainings (to exclude 
fungal infection, data not shown) were constantly ne-
gative. Immunohistochemical staining with MART-1 
(melanoma antigen recognized by T cells 1) antibody 
(which specifically recognizes melanocytes; Fig. 2c) 
showed a normal number of melanocytes in the basal 
epidermal layer, but the HMB-45 antibody (recognizing 
specifically activated melanocytes; Fig. 2d) confirmed 
vigorous melanocytic activation. The S100-antibody 
detected melanocytes as well as epidermal and der-
mal dendritic cells (Fig. 2e). Anti-CD68 (recognizing 
specifically macrophages; Fig. 2f) stained some mela-
nophages in the upper dermis. The clinical picture and 
patient’s history strongly suggested the diagnosis of a 
chemotherapeutic drug-induced benign activation of 
melanocytes in the nail matrix of the right thumb. 
DISCuSSION
Some chemotherapeutic agents are associated speci-
fically with hyperpigmentation of the nails, mucous 
membranes and skin (1). Chemotherapeutic agents 
regularly associated with pigmented nail changes 
include doxorubicin, docetaxel, cyclophosphamide, 
hydroxyurea, and bleomycin (2). Dividing matrix nail 
cells are especially perturbed by antimitotic substances 
generally resulting in a reduced rate of nail plate growth. 
Pigmented nail changes may appear early, one to seve-
ral weeks after initiation of drug intake, due to rather 
unspecific activation of melanocytes in the epidermal 
basal layer of the nail matrix (3). The most common 
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Fig. 1. (a) Clinical presentation of the one-nail brown-band, tapering from 
the basal to the distal part of the nail. (b) Dermatoscopic examination 
demonstrating homogeneous brownish discoloration with continuation into 
the proximal nail fold; neither pigment nests nor pigment dots were detectable.
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pattern consists of longitudinal bands affecting several 
nails (4, 6). In transverse forms of melanonychia, each 
band corresponds to a cycle of therapy (6). For unknown 
reasons, pigmented nail changes mostly affect female 
patients (5). The rather broad differential diagnosis of 
melanonychia striata includes melanoma, nail matrix 
melanocytic naevus, lentigo and lentignoses, ethnic nail 
pigmentation, repetitive trauma-induced pigmentation, 
and subungual haemorrhages (7).
As melanonychia is the initial “red-flag” sign in a 
large percentage of nail melanomas, a careful history 
and physical examination is mandatory. Dermatoscopy 
is able to differentiate between pigmented changes in the 
skin, but in most cases of nail pigmentation this techni-
que is not very helpful. In all cases the possibility of ini-
tial melanoma should be considered, in uncertain cases 
nail biopsy and histological examination performed.
In our patient, melanonychia was monodactylic, 
monochromic, and broader at the proximal parts. The 
patient’s history provided key information about the 
cause of her nail hyperpigmentation, but some degree 
of uncertainty remained. Histological differential diag-
nosis between melanocytic activation and early lentigo 
can be challenging; however, this has no consequences, 
as both are benign lesions (6). Of course, benign nail 
discoloration is not a base for changing or even stopping 
a successful chemotherapy regimen. However, in our 
patient docetaxel, doxorubicin and cyclophosphamide 
was ceased as planned. No further therapy was neces-
sary, and the hyperpigmentation slowly disappeared.
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Fig. 2. Melanin, iron and immunohistochemical staining; 
400× magnification. (a) Strongly positive melanin staining. 
(b) In Iron staining no hemosiderin was detectable. (c) 
Physiological expression of MART-1 in melanocytes. 
(d) Increased HMB-45 expression indicating activated 
melanocytes. (e) Physiological S100 expression of 
melanocytes and dendritic cells. (f) CD68-positive 
melanophages in the upper dermis.
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